Drug Profile
FFP 104
Alternative Names: FFP-104; FFP104-001Latest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator FF Pharma
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action CD40 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crohn's disease; Primary biliary cirrhosis
Most Recent Events
- 08 Oct 2021 No development reported - Phase-II for Crohn's disease in Netherlands, Belgium (IV)
- 08 Oct 2021 No development reported - Phase-II for Primary biliary cirrhosis in Italy, United Kingdom, Netherlands (Parenteral)
- 15 Feb 2019 FFP 104 is still in phase II trials for Crohn's disease and Primary biliary cirrhosis in Belgium, Italy, the Netherlands and United Kingdom (FF Pharma website, February 2019)